Camlin Fine Sciences Limited — PPTs, 11-11-2024: Investor Presentation

**Financial Highlights:** Camlin Fine Sciences reported consolidated revenue of Rs. 4,230 million for Q2 FY25, a growth of 6.9% quarter-on-quarter. The operational EBITDA margin improved to 10.2%, reflecting stronger gross margins at 48.2%. The company faced significant impairment provisions totaling Rs. 1,468 million related to its European and Chinese operations, impacting profitability. The net profit after tax stood at a loss of Rs. 1,161 million.

**Strategic Initiatives and Growth Drivers:** Camlin aims to enhance its product lines, particularly in the aroma segment, with notable growth in aroma sales to Rs. 454 million. The company is investing in R&D to drive forward integration in high-margin blends and developing new products within performance chemicals and specialty ingredients.

**Business Developments:** The acquisition of Vitafor Invest NV aims to expand operations in the European and African pet food markets, providing future synergy with existing customer bases. This acquisition is a strategic move designed to leverage Vitafor’s established network.

**Market Position and Competitive Advantage:** Camlin continues to assert its market leadership in antioxidants while diversifying into higher-margin segments. The company is well-positioned with a global footprint and ongoing innovations in product lines.

**Investor Implications:** There are positive indicators for potential growth, especially with the strategic tie-up and expansions planned in the aroma ingredients sector. However, investors should be aware of the significant impairments that could affect short-term profitability.